XTL BIOPHARMACEUTICALS ANNOUNCES AN AMENDMENT OF THE AGREEMENT FOR THE ACQUISITION OF THE USE PATENT ON RECOMBINANT ERYTHROPOIETIN (rHuEPO) FOR THE TREATMENT OF MULTIPLE MYELOMA